• .

  • .

  • .

  • .

  • .

Copyright 2025 - Integrated Care Services Association

Focus on Atopic Eczema - Anthony Chu, FRCP. Professor of Dermatology

Atopic eczema is one of the commonest of the inflammatory skin diseases and its incidence is increasing. In a recent epidemiologic study, the worldwide incidence of atopic eczema in children and adolescence was 20% and in the UK the incidence of atopic eczema in adults was 8.1% (1). In about 60% of children with atopic eczema other manifestations of the atopic diathesis are present including allergic rhinitis, asthma and multiple type I allergies (1).

Pathophysiology of atopic eczema

It is important to understand the basic pathophysiology of the disease to be able to treat it effectively. This has been detailed in a recent excellent review (2). In atopic eczema, the skin is dry with defective skin barrier function which is considered to be the first step in the development of atopic eczema. Loss of barrier function in the atopic individual is multifactorial with loss of function of filaggrin, a structural protein that is pivotal in the formation of the stratum corneum (3) and a change in composition of stratum corneum lipids due to altered expression of certain enzymes involved their biosynthesis (4). Inflammation in the skin can further alter filaggrin and lipid levels with worsening of xerosis with severity of the eczema (4). 

Infection/colonisation of atopic eczema by Staphylococcus aureus is important in the development and exacerbation of this disease but is often ignored by those treating this disease. Colonisation of atopic eczema with S aureus is very common and may be related to adhesion factors in the epidermis exposed by barrier dysfunction, deficiency of antimicrobial peptides in the atopic, microbial dysbiosis and over expression of Th2/Th17 cytokines. Colonisation with S aureus leads to further disruption of skin barrier function due to superantigens, enzymes and other factors and superantigens will exacerbate the inflammatory response in the skin. A major recent challenge therapeutically is colonisation by methicillin-resistant S aureus.

Managing atopic eczema
Conventional Management

The majority of patients with atopic eczema have mild to moderate disease which can be treated in the community using conventional treatment i.e. emollients and moisturisers, topical corticosteroids or calcinurin inhibitors and anti-infection agents or antibiotics. Treatment of patients is often, unfortunately, inadequate.of patients with atopic eczema have mild to moderate disease which can be treated in the community using conventional treatment i.e. emollients and moisturisers, topical corticosteroids or calcinurin inhibitors and anti-infection agents or antibiotics. Treatment of patients is often, unfortunately, inadequate.

Studies have shown that the regular use of moisturisers reduce dryness of the skin and transepidermal water loss and increased the time to flare of the eczema (5). They are also essential when patients are treated with topical corticosteroids as these agents will increase dryness of the skin. Contact allergic dermatitis to substances found in topical treatments including emollients and topical corticosteroids does occur and patch testing should be considered in patients showing worsening of their symptoms despite adequate treatment (6).

Bleach Baths

The use of bleach baths has radically changed my management of atopic eczema. Use a teaspoon of household bleach (sodium hypochlorite) with liquid emollient in a baby bath or a dessert spoon full in a normal bath and soak for 15 minutes. I use this daily while the eczema is active then reduce to once or twice a week when the skin is in remission. Bleach baths are anti-microbial and will reduce S aureus level but also have anti-flammatory and anti-pruritic effects. Most reports have used the baths twice weekly but patients tolerate daily baths without problem. The use of bleach baths is controversial and studies have suggested that the benefit is no better than plain water baths when used twice weekly (7) but in my experience bleach baths work very well.

Coagulase negative Staphylococcus

Skin commensal bacterial Staphylococcus hominis and Staphylococcus epidermidis produce antimicrobial peptides that can resist S aureus colonisation and studies have shown that transplantation of coagulase negative Staphylococcus onto atopic eczema skin inhibited S aureus (8).

Probiotics

The use of probiotics in atopic eczema is controversial. Studies have shown increased permeability of the intestine and reduced skin micobiome diversity in atopic eczema. Probiotics are considered to improve intestinal permeability and modulate the body’s microbiome and immune status. A systemic review and meta-analysis of controlled trials showed some efficacy in reducing inflammation in atopic eczema (9).

Vitamin D

Vitamin D in atopic eczema remains controversial. Vitamin D is an immune-modulator. Studies have shown a correlation between low vitamin D levels and atopic eczema severity and studies have shown improvement of atopic eczema with vitamin D supplements in those found to be deficient (10). It is certainly worth checking vitamin D levels in your atopic eczema patient failing on conventional treatment.

Topical Coal Tar

Topical coal tar has been used in the treatment of atopic eczema for decades but has largely fallen out of favour due to its smell and messiness. A recent study, however, has shown that its use induces keratinocyte derived antimicrobial proteins and leads to a reduction of Staphylococcus density on the skin (11).

Systemic Immunosuppressants

In patients who fail topical treatments, systemic immunosuppressants are used. The most frequently used is methotrexate. A recent study of long-term methotrexate in childhood atopic eczema showed improvement in 83% and hospitalisation for their eczema reduced by 50%. At a median 2 year follow up after stopping treatment 66% were clear or had mild to moderate eczema (12).

Other systemic immunosuppressant has been successfully used in atopic eczema. Azathioprine was a popular choice but has now been superseded by methotrexate, ciclosporin and mycophenolate mofetil (13).

New Treatments
Dupilumab

Dupilumab is a fully humanised monoclonal antibody that blocks interleukin 4 and interleukin 13 which shows marked and rapid improvement of moderate to severe atopic eczema (14). NICE guidelines published in 2018 are that Dupilumab should be considered in an adult with moderate to sever atopic eczema that has not responded to at least 1 systemic immunosuppressant therapy. The drug should be stopped at 16 weeks if the eczema has not responded adequately. Dupilumab is used subcutaneously at 600mg initially then at 300mg alternate week. The cost of the drug is £27,410 to £28,495 per quality-adjusted life year. Studies have shown its efficacy in children with atopic eczema but it does not yet have a licence for paediatric use.

This is, as with all biologic agents, an expensive treatment with the potential to be over used given our experience with biologic treatment in psoriasis.

Crisaborole

This is a new topical phosphodiesterase 4 inhibitor available in the USA as a 2% ointment for the treatment of mild to moderate atopic eczema. It is not yet licenced for use in UK. Phosphodiesterase type 4 is the primary cAMP metabolizing enzyme involved in the control of activity in inflammatory cells and inhibitors of this enzyme will have an effect in inflammatory dermatosis. Studies have shown good safety and efficacy profile of Crisaborole (15).

Emerging Treatments

A number of drugs are in the pipeline. The JAK-STAT inhibitors are the most promising. Biologic agents: IL4/IL13 antagonists lebrikizumab and tralokinumab and IL31Ra antagonist nemolizumab are also under active investigation (16).The JAK-STAT inhibitors are the most promising. Biologic agents: IL4/IL13 antagonists lebrikizumab and tralokinumab and IL31Ra antagonist nemolizumab are also under active investigation (16).

The Dire State of Dermatology in the UK

Considering that a high percentage of a GPs work is dermatological, teaching of dermatology in UK medical schools is generally rudimentary or in some schools only an option. Dermatology positions for GP trainees are very few. Of the 738 consultant dermatologist positions in the UK to serve a population of over 60 million, 257 are at present unfilled. There are 237 training positions in dermatology but many will want part time jobs and many consultants are leaving the NHS early due to the changes in the NHS. Given the restriction on what we can provide in the NHS and the threat of dermatology services being put out to tender and taken over by private providers I can fully understand this. The people who suffer are the patients with dermatologic conditions. Few skin diseases are fatal but many have severe impacts on the quality of life of the sufferer and these patients need a good and robust dermatology service.

References

  1. Kowalska-Oledzka E, Czarnecka , Baran A. Epidemiology in atopic dermatitis in Europe. J Drug Assess 2019; 8:126-128.
  2. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc 2019; 40:84-92
  3. Sandilands A, Sutherland C, Irvine AD, Inwin McLean WH, Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci. 2009;122:1285-94.
  4. Danso M, Boiten W, van Drongelen et al. Althered expression of epidermal lipid bio-synthesis enzymes in atopic dermatitis skin is accompanied by changes in stratum corneum lipid composition. J Dermatol Sci 2017;88:57-66
  5. Pohar R, McCormack S. Emollient treatments for atopic dermatitis: Review of clinical effectiveness, cost-effectiveness and guidelines. Canadian Agency for Drugs and Technologies in Health 2019 (CADTH rapid response report: summary with critical appraisal)
  6. Teo Y, McFadden JP, White IR et al. Allergic contact dermatitis in atopic individuals: Results of a 30 year retrospective study. Contact Dermatitis 2019;10.1111/cod. 13363
  7. Chopra R, Vakharia PP, Sacotte R, Silverberg JI. Efficacy of bleach baths in reducing severity of atopic dermatitis: A systemic review and meta-analysis. Ann Allergy Asthma Immunol 2017;199:435-440
  8. Nakatsuji T, Chen TH, Narala S et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med 2017; 9:eaah4680
  9. Huang R, Ning H, Shen M et al. Probiotics for treatment of atopic dermatitis in children: a systemic review and meta-analysis of randomised controlled trials. Front Cell Infect Microbiol 2017;7:392
  10. Quirk S, Rainwater E, Shure A, Agrawal DK. Vittamin D in atopic dermatitis, chronic urticaria and allergic contact dermatitis. Expert Rev Clin Immunol 2016;12:839-47.
  11. Smits JPH, Ederveen THA, Rikken G et al. TARgetting the cutaneous microbiota in atopic dermatitis by coal tar via AHA-dependent induction of antimicrobial proteins. J Invest Dermatol 2019;S0022-202X(19)325445-X, doi: 10.1016/j,jid.2019.06.142
  12. Purvis D, Lee M, Agnew K et al. Long-term effect of methotrexate for childhood atopic dermatitis. J Paediatr Child Health 2019; 10.1111/jpc. 14478.
  13. Phan K, Smith SD.Mycophenolate mofetil and atopic dermatitis: systemic review and meta-analysis. J Dermatolog Treast 2019;:1-5. Doi:10.1080/09546634.2019.1642996.
  14. Beck LA, Thaci D, Hamilton JD et al. Dupilumab treatment in adults with moderate to severe atopic dermatitis. N Engl J Med 2014;371:130-9.
  15. Zane LT, Kircik L, Call R et al. Crisaborole topical ointment in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open label, maximal use systemic exposure study. Paediatr Dermatol 2016;33:380-387.
  16. Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for topic dermatitis, Paediatr Drugs 2019;21:239-260

Content provided by Anthony Chu, FRCP. Professor of Dermatology.

Indoor air pollution and relevance for the NHS - Professor Nicola Carslaw, University of York

PollutantsContext

In developed countries such as the UK, it has been estimated that we spend around 85-90% of our time indoors, including in our homes, at work and commuting between the two. However, with the exception of occupational exposures, regulation around air pollution exposure focuses almost entirely on outdoor air pollution. If we want to fully understand our exposure to air pollution and then make sound suggestions on how to reduce it, we need to consider indoor air pollution as well as that from outdoors.

Indoor air pollution

Some of the pollution we are exposed to indoors comes from outdoors, for instance through open windows and doors. If a residence or workplace is on a busy road, the traffic could be a major source of indoor air pollutants. Indoor sources include activites such as cooking, fuel burning on open fires or inefficient/poorly-maintained stoves, cleaning, DIY activities, smoking and use of persnoal care products and air fresheners.

There are also sources of pollution from furnishings and building materials, as well as bio-effluents (e.g. carbon dioxide) from people. Finally, chemical and physical interactions between pollutants and building surfaces can make further pollutants. The indoor air quality in a building will therefore depend on its location, how it is ventilated (natural or mechanical) and what activities are going on inside it.

The drive to increase energy efficiency through increased insulation in recent years, has led to increasingly airtight buildings and species emitted indoors take longer to be diluted and removed. It is vital that indoor sources are considered as well as those outdoors when trying to understand the overall exposure (and consequent health effects) of an individual. Otherwise, by trying to avoid one source of pollution, you may inadvertently expose an individual to higher pollutant concentrations.

An obvious example might be shutting the windows of a residence to avoid traffic exhaust from cars outside, but then being exposed to undiluted cigarette smoke being generated by a smoker indoors. Smoking is well known to cause adverse health effects, but some of the activities mentioned above can also generate harmful pollutants. For instance, cleaning and cooking can lead to the production of particulate matter and the use of fragranced products can produce formaldehyde, both of which are associated with adverse health effects.

Relevance for the NHS

There are two main issues for the NHS when it comes to indoor air pollution. The first is around those presenting with conditions that are exacerbated by exposure to air pollution. In this case, a health care specialist might reasonably suggest that the individual avoids exposure to polluted areas such as adjacent to busy roads, or avoids exercise outdoors when outdoor pollution is high. This would only be good advice if the indoor environments used by that individual are known to be free of sources of pollution that also worsen their condition. Adverse health outcomes have been shown to increase as ventilation decreases, so shutting the window is not always a good solution without understanding all of the sources an individual is exposed to.

The second issue is around the healthcare environments themselves. An obvious step would be to avoid fragranced products (e.g. cleaning products) in these settings, and also, thinking about the time of day when cleaning is carried out. Indoor chemistry (and hence the processes that drive production of harmful secondary products) tends to be driven by outdoor ozone, which is higher in the afternoons, especially in summer. Cleaning in the morning could therefore lead to lower concentrations of some pollutants indoors than if cleaning were carried out in the afternoon. The appropriateness of some of the air cleaning devices that are marketed to remove bio-pathogens should also be considered. Whilst some of these may be effective, others are less so and some use chemical reactions internally that can cause harmful products to be emitted upon use. As these devices are largely unregulated at the moment, it is important to understand the full impacts of any instrument used in a healthcare setting, both chemically and biologically.

Open window

What can be done?

There are several things that can be done to lower exposure to indoor pollutants in any setting. Avoid unnecessary personal care product use, use cream products instead of spray products and use a cooker hood (that ventilates outdoors) while cooking. Ventilate regularly with outdoor air if it is relatively clean: if you live near a road, use a window on the other side of the building. In summer, if outdoor ozone is high and windows are open to keep a building cool, consider avoiding cleaning activities until outdoor ozone is lower.

Further Reading

The US-EPA site on indoor air quality provides some excellent background information on indoor air quality www.epa.gov/indoor-air-quality-iaq

Read about the WHO air quality guidelines for indoor air pollutants: www.euro.who.int/en/health-topics/environment-and-health/air-quality/publications/2010/who-guidelines-for-indoor-air-quality-selected-pollutants

This paper reviews indoor chemistry: Weschler CJ, Carslaw N (2018) Indoor Chemistry. Environmental Science and Technology 52: 2419–2428. doi: 10.1021/acs.est.7b06387

And this one presents a review of data around adverse health effects and lower ventilation rates: Sundell, J., Levin, H., Nazaroff, W.W., Cain, W.S., Fisk, W.J., Grimsrud, D.T., Gyntelberg, F., Li, Y., Persily, A.K., Pickering, A.C., Samet, J.M., Spengler, J.D., Taylor, S.T. and Weschler, C.J. (2011) Ventilation rates and health: multidisciplinary review of the scientific literature, Indoor Air, 21, 191-204.

Content provided by Professor Nicola Carslaw, University of York. For more information please email This email address is being protected from spambots. You need JavaScript enabled to view it..

Health impacts of air pollution in the UK - Professor Helen ApSimon - Imperial College London, and Dr Mike Holland - Imperial College & EMRC

Despite huge improvements since the intense pollution smogs of the 1950s, the impacts of air pollution on human health remain a major problem in the UK. Before the Clean Air Acts of 1956 and 1968, triggered by the Great London Smog of 1952, the main concerns were emissions of sulphur dioxide and particles from coal burning. These have fallen substantially given strict legislation and wide-spread switching from coal to gas, and more recently solar and wind energy. However there has been growth of other pollutants, in particular from traffic, and from emerging trends such as domestic wood burning.

Understanding of the health impacts of air pollution has grown substantially since the 1980s through the publication of a large literature on epidemiological research in the UK and many other countries. Early work linked mortality and respiratory hospital admissions to exposure to fine particles. This has since expanded to include a broader range of pollutants and effects. With respect to exposure to pollutants in the ambient air, most attention in the UK and Europe is now focused on three pollutants, fine particles (PM2.5) which can penetrate deep into the lungs, nitrogen dioxide (NO2), and ozone formed as a secondary pollutant from chemical reactions in the atmosphere. Although various suggestions have been made that some particles, such as those in diesel exhaust, could be more harmful than others, the particles present at any location are a combined mixture from multiple sources and relative toxicities have not been established.

Information from the epidemiolocal studies can be used to derive response functions that enable the impacts of exposure to be estimated when combined with data on pollutant concentrations and population. The UK’s Committee on the Medical Effects of Air Pollutants (COMEAP) has estimated the mortality burden of air pollution in the UK from exposure to fine particles PM2.5 and nitrogen dioxide, NO2, in 2013, indicating a mortality burden of between 328,000 and 416,000 years of life lost across the population every year. This translates to between 28,000 and 36,000 equivalent attributable deaths. A study by the Royal College of Physicians provides a higher estimate of 40,000 equivalent attributable deaths per year, but includes ozone as well as NO2 and PM2.5 (www.rcplondon.ac.uk/projects/outputs/every-breath-we-take-lifelong-impact-air-pollution). The RCP report highlighted a wide range of health impacts affecting all stages of human life from the womb to old age. These include links between air pollution and cancer, asthma, stroke and heart disease, diabetes, obesity and changes linked to dementia – all of them being illnesses of high concern for the NHS.

What is being done about it

Recognition of these problems has led to international and national steps to improve the situation; which is illustrated below by a map of annual average PM2.5 concentrations in 2016, and indicates around 15 million people in the UK are exposed above the WHO standard of 10 micrograms per cubic metre (µg.m-3). The worst areas in red are clearly correlated with cities and urban populations, where effects of local sources are superimposed on a background from national sources, long-range contributions imported from other countries and shipping, and including secondary particles formed by chemical reactions in the atmosphere. International action under the UNECE Air Convention and the European Commission has led to the setting of ceilings for emissions from each country to control the transboundary imported pollution including PM2.5 and ozone. The distribution of nitrogen dioxide is even more concentrated in urban areas, but is mainly due to local sources, particularly traffic.

Annual average PM2.5 concentrations in 2016

Annual average PM2.5 concentrations in 2016 (UKIAM model) 

www.gov.uk/government/publications/air-quality-assessing-progress-towards-who-guideline-levels-of-pm25-in-the-uk

Reduction of air pollution at the national level is being addressed in Defra’s “Clean Air Strategy” as published in January 2019, and covering pollutant emissions from transport, at home, from farming and from industry (www.gov.uk/government/publications/clean-air-strategy-2019). An announcement by Michael Gove while still Environment Minister set a commitment to work towards attainment of the WHO standard of 10µg.m-3 for PM2.5, which is very much tighter than the current legal limit value of 25 µg.m-3 set by EU legislation; and will require substantial reduction in emissions of both primary particles and gaseous precursors of secondary particles. Action at the city level is also focused on reducing pollution, particularly NO2 concentrations; with measures like low emission zones and encouraging travel by walking, cycling or public transport. Changes in individual behaviour to help improve health are also needed to complement regulatory measures, and this requires wider awareness of the sources of air pollution and their consequences. It is also important to take a broader perspective, where for example the benefits of improved physical fitness from cycling or walking for short journeys can outweigh any disbenefits of exposure to air pollution, especially if there are suitable routes available. The medical profession can play an important role here in recognising connections between air pollution and health; and disseminating information to patients and the public.

The role of the NHS

As one of the world’s largest organisations (in terms of staff, behind only the US and Chinese military, McDonalds and Walmart), and costing the equivalent of around 6% of the UK’s GDP, it is not surprising that the NHS uses a significant quantity of energy for space and water heating, lighting and running equipment, and transport. For some years, the NHS Sustainable Development Unit (SDU) has investigated the carbon footprint of the health service. Recognising the NHS’ responsibility for health protection, SDU launched HOTT (Health Outcomes of Travel Tool) in 2017, which quantifies the health burden of air pollution and noise from transport linked to the NHS, along with accidents and greenhouse gas emissions. Version 3 of the tool has recently been released (www.sduhealth.org.uk/delivery/measure/health-outcomes-travel-tool.aspx). A future extension to HOTT will also quantify the air pollution impacts and GHG emissions of energy use by NHS Trusts.

HOTT provides analysis for NHS organisations at the level of individual CCGs, Ambulance Trusts and non-ambulance Providers such as hospital Foundation Trusts. The model uses up to date information on patient and staff numbers, travel distances, pollutant emissions and pollutant damage costs derived by Defra that cover the following outcomes for the two major transport pollutants:

  • PM2.5: mortality, respiratory and cardiovascular hospital admissions, stroke, chronic heart disease, asthma and productivity
  • NO2: mortality, respiratory hospital admissions, asthma, diabetes, productivity

As an illustration, results indicate 12.4 billion miles a year of travel linked to the activities of ambulance trusts, primary care and CCGs, and other providers in the NHS, with an associated estimate of health damage costs from air pollution of £162 million in 2018.

The HOTT tool allows users to develop their own future scenarios for transport provision, for example promotion of active travel, modal shift from cars to public transport and increasing the rate of electrification for the vehicle fleet, to see how these will affect future performance. Results can be used to assist in developing the business case for investment in cleaner and safer travel. There is also the potential for the NHS to use HOTT more widely, considering the travel burdens linked to other major organisations, such as universities, local authorities and private enterprises, and collaborating to increase the shift to more sustainable travel.

Content provided by Professor Helen ApSimon - Imperial College London, and Dr Mike Holland - Imperial College & EMRC

Why the Long Term Plan offers an opportunity for change in mental health - Geoff Heyes, Head of Health Policy and Influencing at Mind

In recent years leaders in the health and voluntary sectors have welcomed many mental health promises, from additional funding to innovative ideas for care in the community. But we should not underestimate the opportunity available now to change things at a national level and in communities for people living with mental health problems.

The publication of the NHS Long Term Plan was a mental health milestone, which recognised that mental health underpins almost all areas of health, and committed £2.3bn of ring-fenced funding a year for it. The plan is ambitious, including promises to support pregnant women and new mums, improve community care and increase people’s access to treatment like counselling and cognitive behavioural therapy. Importantly, it recognises the urgency of improving mental health services for children; many problems begin before the age of 18 and if younger people get the support they need, it can help to prevent more problems from becoming more acute.

The plan provides a huge opportunity to create the kind of mental healthcare most of us would want for ourselves and our families. We are now at the stage where this needs to be translated into reality at a local level.

The NHS recently published its mental health implementation framework - developed and tested with many of the same stakeholders as for the plan - setting out further detail for local areas on how the plan can be delivered. These local areas (Sustainability and Transformation Partnerships (STPs) and Integrated Care Systems (ICSs)) are now working up their own, detailed five-year plans.

At Mind, we expect this process to involve as many people with lived experience of mental health problems as possible, as well as experts in the sector, like local Mind branches, which are well placed to ensure the plans propose practical action to meet the community’s needs.

We know that in some parts of the country service users and those with first-hand experience of mental health problems are being included from the very start of the process. In Cornwall and the Isles of Scilly a wide-range of people including those who have used mental health services, young people, providers of services, and patient representatives, including Healthwatch, have helped to shape and influence its draft mental health strategy.

“We knew from the start that it was of critical importance to involve people with first hand experiences of using our services in the development of our plans. We would not be able to realise our vision, and deliver a plan that meets people’s needs without their involvement,” Dr Iain Chorlton, NHS Kernow’s chairman said.

NHS Kernow is now finalising plans to share Cornwall and the Isles of Scilly’s draft mental health strategy with the wider public to get their thoughts on its plan. What people say about the strategy will be used to update the draft strategy before its final submission by the end of the year.

This example shows what is possible and Mind will continue to hold to account those in power at a national and a local level, to ensure that a similar process takes place across the country and every promise is delivered. We should not underestimate the scale of the challenge in ensuring the money ear-marked for mental health reaches the frontline and that national policy is translated into meaningful local action.

Because, behind these promises and processes, and despite significant change particularly in the last five years, there is still much to do to improve in the experiences of people trying to access NHS mental health services. No one can deny that mental health is on the agenda like never before, in part proved by its profile in the Long Term Plan, but we are still feeling the effects of underfunding every day. We know that much of the time people only get help once they reach crisis point and, in total, fewer than four in ten people with a mental health problem get any kind of support at all.

As much as a lot is riding on these local plans to set the direction of travel for the coming five years, local decision makers must also not lose sight of the fact that we are in the middle of an existing five-year plan for mental health services. When Mind helped develop the Five-Year Forward View for Mental Health in 2016, we did it with an understanding that new plans take time to get going, which made 2019 a critical year for delivery.

On top of this, we also need to see a strategy which shows that the government will tackle the social issues often underlying poor mental health, like changes to the benefits system, poor quality housing, insecure employment, pressures in schools and a lack of social care.

People with mental health problems deserve better and only when we start to hear that people can get the support they need, when they need it, will we feel that we are making sufficient progress. Change is possible, but only with the full commitment and participation of the NHS and its partners from top to bottom. Proof of delivery will be in the experiences of people trying to access the services they need.

Mind Logo

Content provided by Geoff Heyes, Head of Health Policy and Influencing at Mind. For more information please visit www.mind.org.uk.

f t g m